Young patients diagnosed with neuroblastoma (NB), a rare form of pediatric cancer that accounts for between 6 and 10 percent of childhood cancers, often face post-treatment challenges including relapse and drug resistance, as well as toxic side effects from chemotherapy or radiation therapy.
Neuroblastoma, an extracranial solid tumor, has its start very early in life—in the immature nerve cells of a developing fetus—and diagnosis is usually made during infancy or the first few years of life.
